Europe Viral Vector Manufacturing Market

Europe Viral Vector Manufacturing Market Size (2023 to 2028)

The Europe viral vector manufacturing market size is forecasted to grow at a CAGR of 20.31% from 2023 to 2028 and be worth USD 457.97 million by 2028 from USD 181.69 million in 2023.

The increase in the number of viral vector clinical trials, the availability of funding for gene therapy development, and the prevalence of genetic diseases, cancer, and infectious diseases year over year are driving the growth of the European viral vector manufacturing market.

Europe's viral vector production industry is booming thanks to an increase in gene therapy-based products. Furthermore, advances in molecular biology have accelerated genetic sequencing, which is expected to improve precision medicine further. Gene therapy is getting closer to a breakthrough because of advances in molecular biology and medical research, allowing viral vector production to scale up and revolutionize patient care. The key drivers of considerable R&D investments in viral vector-based cancer treatments driving market expansion include the high need for efficient cancer medicines, a fast-track approval process, and innovative drugs' potential to become blockbuster products.

Due to an increase in gene therapy approvals and, as a result, growth in manufacturing capabilities, competition in this industry is projected to heat up shortly. As a result, the companies collaborate on advanced gene therapy as a successful global leadership strategy. While some viral vector manufacturing market participants focus on collaboration programs, others focus on extending their current viral vector manufacturing capabilities, strengthening their position as viral vector manufacturing industry leaders.

The limited lifespan of virus vectors is a disadvantage. In addition, the high expense of gene-based medical therapies in Europe may limit viral vector demand. Time-consuming and highly regulated vector production processes and insufficient capacity for vector production are some of the other critical restrictions on the market for viral vectors and plasmid DNA manufacture.

The reduced immunogenicity found in smallpox-vaccinated individuals is a drawback of vaccinia virus vectors. Immunity to the poxvirus could diminish the vaccine's effectiveness. According to several clinical research, pre-existing immunity has a moderate effect. These factors are predicted to restrain the Europe Viral Vector Manufacturing Market during the forecast period.

This research report on the European viral vector manufacturing market has been segmented into the following categories.

By Type:

• Adeno-Associated Viral Vectors
• Retroviral Vectors
• Adenoviral Vectors

By Application:

• Gene Therapy
• Vaccinology Development

By Disease:

• Cancers
• Genetic Disorders
• Infectious diseases
• Other Diseases

By Country:

• UK
• France
• Spain
• Germany
• Italy
• Russia
• Sweden
• Denmark
• Switzerland
• Netherlands
• Turkey
• Czech Republic
• Rest of Europe

Geographically, Europe accounted for the second-largest share of the global viral vector manufacturing market in 2023, a trend expected to continue for several years. The expanding prevalence of genetic abnormalities, cancer, and infectious diseases, the increasing number of clinical trials using viral vectors, financing for gene therapy development, and future uses in new drug delivery systems are all driving the business ahead.

Clinical research for rare diseases has risen to the forefront in the United Kingdom due to government encouragement and patient involvement. For a combination of reasons, including a high rate of novel medicine adoption and an increased incidence rate of chronic diseases, the United Kingdom has the most significant market share in Europe. Furthermore, the increased frequency of genetic and other chronic illnesses, an aging population, the rising need for targeted and personalized treatment, and favorable government initiatives drive future market expansion in the United Kingdom.

The German cell and gene therapy market has recently gained traction in product approvals and pipeline programs. This is attributable to the introduction of streamlined regulatory routes, more significant private and governmental investment, and expanding healthcare demands. In addition, unmet personalized medicine needs drive regenerative medicine research, leading to a higher demand for viral vector supply.

KEY MARKET PLAYERS:

FUJIFILM Diosynth Biotechnologies, Thermo Fisher Scientific, Cobra Biologics, Catalent Inc., Wuxi Biologics, Takara Bio Inc., Waisman Biomanufacturing, Genezen laboratories, Batavia Biosciences, Miltenyi Biotec GmbH, SIRION Biotech GmbH, Virovek Incorporation, BioNTech IMFS GmbH, and Audentes Therapeutics are a few of the noteworthy companies operating in the European viral vector manufacturing market.